 Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees 53.34 per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally. Cipla had earlier said pricing would not exceed 5,000 rupees. On Tuesday, Sovereign Pharma, which is manufacturing and packaging the drug for Cipla, said it had dispatched the first batch. 